Ingenion Medical wins Innovate UK grant for CE Marking its novel urinary catheter

London, UK – 06 November, 2020Ingenion Medical Limited, today, announces it has been awarded nearly £100,000 in grant funding from Innovate UK, the country’s innovation agency.

Ingenion will use the proceeds over the next six months to gain a CE Mark for its CymActive™ urinary catheter, a novel medical device to treat male patients suffering from chronic urinary retention.

Ingenion’s CEO Edward Cappabianca said, “Our technology’s proprietary, patent-pending magnetic valve lets patients control their urination, without surgery or drugs.”

The device, designed to work with the body’s natural defences, is expected to reduce the incidence of Catheter Associated Urinary Tract Infections (CAUTIs), significant contributors to hospital acquired infections and patient mortality.

Alistair Taylor, Chairman of Ingenion Medical, added, “This is an excellent opportunity for Ingenion to advance technology to benefit urinary retention patients. We anticipate the CymActive™ catheter will be first from our innovation pipeline to launch. We are committed to improving the health and quality of life for men and women sufferings from urinary control dysfunctions.”

About Ingenion Medical Limited: Privately held, UK-based Ingenion Medical Limited develops, manufactures, and commercializes a family of products for chronic urinary retention and incontinence patients. CymActive™, its lead product, is a novel urinary catheter which can remain in-dwelling for 28 days, a dramatic quality of life improvement versus legacy solutions that often requiring multiple catheters in a single day, a common cause of infection. Visit us at: ingenionmedical.co.uk

About Innovate UK:
Innovate UK is part of UK Research and Innovation. We are the UK government’s innovation agency. Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We work with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. Find out more about what we do.

INGN-001

#

Upcoming 10x Healthcare Conference In London

17 February 2020 

Ingenion Medical Limited will be participating in the upcoming 10x Healthcare Conference in London. The 10x Medical Device Conference is a dynamic event allowing the medical device industry to network and enhance your skills. Each year the conference creates strong relationships amongst large players in the medical device industry. These relationships teach attendees new and more efficient ways of accomplishing tasks with industry-recommended resources. The 10x event is catered towards junior, mid-level, or senior professionals in the industry.

Upcoming 38th Annual JP Morgan Healthcare Conference

12 – 16 January 2020

Edward Cappabianca will be attending the upcoming 38th Annual JP Morgan Healthcare Conference. This is the largest and overall most informative healthcare investment symposium. Annual conferences bring together industry leaders, innovative creators, investment community members, and emerging companies. The JP Morgan Annual Healthcare Conference began in 1983. In its earliest stages, the annual conferences featured only 20 companies, admitted roughly 200 attendees, and strictly focused on the biotech industry. Today the conference brings local and international investors and executives together. Companies encompass the entire healthcare landscape, largely pharmaceutical companies, medical device companies, and healthcare service providers.

Edward Cappabianca Appointed As CEO

18 November 2019

Ingenion Medical Limited appoints new CEO, Edward Cappabianca. Mr. Cappabianca is an experienced Managing Director & Investment Banker with a demonstrated history of the biotechnology industry. He graduated the University of Virginia in 1987 obtaining his BA in Chemistry/Biochemistry. He eventually went on to obtain is MBA in 1991 from the Wharton School of Finance. Mr. Cappabianca has served as the CEO of two early-stage life science companies. In addition, he has raised over $2 Billion USD in a range of financings from private & public equity to private debt and grant funding.  Through his education and experience, Mr. Cappabianca has strong business development professional skills in Medical Devices, Venture Capital, Biotechnology, IPO, and Mergers & Acquisitions.